Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.01
-0.25 (-3.03%)
At close: Aug 28, 2026, 4:00 PM EDT
8.03
+0.02 (0.25%)
After-hours: Aug 28, 2026, 7:52 PM EDT
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 975 employees as of December 31, 2025. The number of employees increased by 137 or 16.35% compared to the previous year.
Employees
975
Change (1Y)
137
Growth (1Y)
16.35%
Revenue / Employee
$333,302
Profits / Employee
-$296,941
Market Cap
3.63B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 975 | 137 | 16.35% |
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| AbCellera Biologics | 562 |
| Denali Therapeutics | 507 |
| Structure Therapeutics | 281 |
| uniQure | 221 |
| IDEAYA Biosciences | 145 |
IOVA News
- 5 days ago - Iovance Biotherapeutics price target raised to $10 from $7 at TD Cowen - TheFly
- 8 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Iovance Biotherapeutics price target raised to $7 from $4 at UBS - TheFly
- 12 days ago - Iovance Biotherapeutics price target raised to $11 from $10 at Mizuho - TheFly
- 13 days ago - Iovance Biotherapeutics put volume heavy and directionally bearish - TheFly
- 23 days ago - Iovance Biotherapeutics price target raised to $6 from $4 at Baird - TheFly
- 23 days ago - Iovance Biotherapeutics price target raised to $8 from $5 at Citizens - TheFly
- 23 days ago - Iovance Biotherapeutics price target raised to $13 from $11 at Barclays - TheFly